Nonsynonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules

AIDS Research and Human Retroviruses

Volumn 14, Issue 3, 1998, Pages 241-248

  Birk, Markus ^a   Vahlne, Anders ^a   Sönnerborg, Anders ^a   Sällberg, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; MATRIX PROTEIN; PROTEIN P17; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIGEN RECOGNITION; ARTICLE; CLINICAL ARTICLE; CONSENSUS SEQUENCE; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; HLA SYSTEM; HLA TYPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR CLONING; MOLECULAR EVOLUTION; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0032502019     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.241     Document Type: Article

References (38)

1. Mervis RJ, Ahmad N, Lillehoj EP, Raum MG, Salazar FHR, Chan HW, and Venkatesan S: The gag gene products of human immunodeficiency virus type 1: Alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative Gag precursors. J Virol 1988;62:3993-4002.
2. Graham S, Follett EA, Wallace L, Desselberger U, and Marsden HS: Immunodominant epitopes of HIV-1 p17 and p24. AIDS Res Hum Retroviruses 1992;8:1781-1788.
3. Metha SU, Rupprecht KR, Hunt JC, Kramer DE, McRae BJ, Allen RG, Dawson GJ, and Devare SG: Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection. AIDS Res Hum Retroviruses 1990;6:443-154.
4. Achour A, Picard O, Zagury D, Sarin PS, Gallo RC, Naylor PH, and Goldstein AL: HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. Proc Natl Acad Sci USA 1990;87:7045-7049.
5. Johnson RP and Walker BD: Cytotoxic T lymphocytes in human immunodeficiency virus infection: Responses to structural proteins. Curr Top Microbiol Immunol 1994;189:35-63.
6. Nixon DF, Broliden K, Ogg G, and Broliden P-A: Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992;76:515-534.
7. Quinones-Mateu ME, Holguin A, Dopazo J, Najera I, and Domingo E: Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env. AIDS Res Hum Retroviruses 1996;12:1117-1128.
8. Markham RB, Yu X, Farzadegan H, Ray SC, and Vlahov D: Human immunodeficiency virus type 1 env and p17 gag sequence variation in polymerase chain reaction-positive, seronegative injection drug users. J Infect Dis 1995;171:797-804.
9. Yoshimura FK, Diem K, Gerald H, Learn J, Riddell S, and Corey L: Intrapatient variation of the gag gene of human immunodeficiency virus type 1 plasma virions. J Virol 1996;70:8879-8887.
10. Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A, et al.: HIV-1 p17 synthetic peptide vaccine HGP-30: Induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Cell Mol Biol 1995;41:401-407.
11. Weber J, Cheingsong-Popov R, Callow D, Adams S, Patout G, Hodgin K, Martin S, Gotch F, and Kingsman A: Immunogenicity of yeast recombinant p17/p24 virus like particles: Ty virus like particles (p24-VLP) in health volunteers. Vaccine 1995;13:832-834.
12. Berggren RE, Wunderlich A, Ziegler E, Schleicher M, Duke RC, Looney D, and Fang FC: HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. J AIDS 1995;10:489-495.
13. Eron JJJ, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangko BG, Pate PG, Torres RA, Mitsuyasu RT, and Twaddell T: Randomised trial of MNrpg120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996;348:1547-1551.
14. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, SJ OB, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, and Mann DL: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med 1996;2:405-411.
15. Ada GL and McElrath MJ: HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy. AIDS Res Hum Retroviruses 1997;13:205-210.
16. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, et al.: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med 1995;1:59-64.
17. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstmann KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT, et al.: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-542.
18. McAdam S, Klenerman P, Tussey L, Rowland-Jones S, Lalloo D, Phillips R, Edwards A, Giangrande P, Brown AL, Gotch F, et al.: Immunogenic HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T lymphocyte responses. J Immunol 1995;155:2729-2736.
19. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR, et al.: Human immunoderficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (London) 1991; 354:453-459.
20. Weiner AJ, Erickson AL, Kansopon J, Muchmore E, Hughes AL, Houghton M, and Walker CM: Persistent hepatitis C virus infection in a infected chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995;92:2755-2759.
21. Rodrigo AG and Mullins JI: Human immunodeficiency virus type 1 molecular evolution and the measure of selection. AIDS Res Hum Retroviruses 1996;12:1681-1685.
22. Olerup O and Zetterquist H: HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-235.
23. Group T10: http://hiv.web.lanl.gov/immuno/index.html. HIV Molecular Immunology Database. Los Alamos National Laboratory, Los Alamos, New Mexico, 1996.
24. Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, Buchanan TM, and Walker BD: HIV-1 Gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the Gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 1991;147:1512-1521.
25. Jassoy C, Johnson. RP, Navia BA, Worth J, and Walker BD: Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex. J Immunol 1992;149:3113-3119.
26. DiBrino M, Parker KC, Shiloach J, Turner RV, Tsuchida T, Garfield M, Biddison WE, and Coligan JE: Endogenous peptides with distinct amino acid anchor residue motifs bind to HLA-A1 and HLA-B8. J Immunol 1994:152:620-631.
27. Karlsson AC, Lindback S, Gaines H, and Sonnerborg A: Characterization of the viral population during primary HIV-1 infection. 1977 (submitted).
28. Cornelissen M, Kampinga G, Zorgdrager F, and Goudsmit J: Human immunodeficiency virus type I subtypes defined by env show high frequency of recombinant gag genes. J Virol 1996;70: 8209-8212.
29. Sutton J, Rowland-Jones S, Rosenberg W, Nixon D, Gotch F, Gao XM, Murray N, Spoonas A, Driscoll P, Smith M, et al.: A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol 1993;23:447-453.
30. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-126.
31. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267: 483-489.
32. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 1995;373:117-122.
33. Preston BD, Poiesz BJ, and Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988;242:1168-1171.
34. Van de Peer Y, Janssens W, Heyndrickx L, Fransen K, van der Groen G, and De Wachter R: Phylogenetic analysis of the env gene of HIV-1 isolates taking into account individual nucleotide substition rates. AIDS 1996;10:1485-1494.
35. McNearney T, Hornickova Z, Markham R, Birdwell A, Arens M, Saah A, and Ratner L: Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci USA 1992;89:10247-10251.
36. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG, McAdam S, Klenerman P, Koppe B, Sigmund K, Bangham CR, et al.: Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature (London) 1995;375:606-611.
37. Falk K, Rotzschke O, Stevanovic S, Jung G, and Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (London) 1991; 351:290-296.
38. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, and Sette A: Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-937.